LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

No evidence of human transmission, but virus found in increasing number of animals World Health Organization says H5N1's risk ...

The Irish Patients Association is calling on parents and guardians of children to join together with them in ‘Flunion’ in the ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the ... FluMist is anticipated to launch for the 2024-2025 flu season. Physician’s ...

Last month, following the inaugural Childhood Influenza Policy Steering Committee (CIPSC), organised and funded by AstraZeneca ... there is no one-size fits all vaccine programmes - national ...

In collaboration with AstraZeneca Plc AZN ... Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. 2024 vaccine sales are expected to grow high single ...

Rwanda has been stepping up measures to combat Rift Valley Fever (RVF) following the country's second outbreak in two years, ...

AstraZeneca reaffirmed its commitment to combating infectious ... In addition, vaccine effectiveness data on FluMist, the only self-administered flu vaccine approved in the US, will be presented. Real ...